Natera

Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities

AnalystConsensusTarget

Not Invested

Consensus Narrative from 20 Analysts

Published

11 May 25

Updated

28 Aug 25

AnalystConsensusTarget's Fair Value

US$197.80

15.1% undervalued

28 Aug

US$167.88

42.0%

1.4%

42.0%

1.4%

Author's Valuation

US$197.8

15.1% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

US$197.8

15.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

13.25%

Biotech revenue growth rate

12.07%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$108.62m

Earnings '28

341.40x

PE Ratio '28

US$37.08b

Market Cap '28

US$37.08b

Market Cap '28

154.20m

No. shares '28

US$240.48

Share Price '28

US$240.48 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$197.54

Fair Value '25